CARM
Price
$0.44
Change
-$0.02 (-4.35%)
Updated
Jan 17 closing price
Capitalization
18.4M
PRME
Price
$2.89
Change
+$0.02 (+0.70%)
Updated
Jan 17 closing price
Capitalization
379.05M
47 days until earnings call
Ad is loading...

CARM vs PRME

Header iconCARM vs PRME Comparison
Open Charts CARM vs PRMEBanner chart's image
Carisma Therapeutics
Price$0.44
Change-$0.02 (-4.35%)
Volume$162.82K
Capitalization18.4M
Prime Medicine
Price$2.89
Change+$0.02 (+0.70%)
Volume$480.24K
Capitalization379.05M
CARM vs PRME Comparison Chart
Loading...
CARM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CARM vs. PRME commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CARM is a Hold and PRME is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (CARM: $0.44 vs. PRME: $2.89)
Brand notoriety: CARM and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CARM: 56% vs. PRME: 41%
Market capitalization -- CARM: $18.4M vs. PRME: $379.05M
CARM [@Biotechnology] is valued at $18.4M. PRME’s [@Biotechnology] market capitalization is $379.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CARM’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • CARM’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, both CARM and PRME are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CARM’s TA Score shows that 4 TA indicator(s) are bullish while PRME’s TA Score has 4 bullish TA indicator(s).

  • CARM’s TA Score: 4 bullish, 4 bearish.
  • PRME’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CARM and PRME are a good buy in the short-term.

Price Growth

CARM (@Biotechnology) experienced а -6.47% price change this week, while PRME (@Biotechnology) price change was -1.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

CARM is expected to report earnings on May 15, 2023.

PRME is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($379M) has a higher market cap than CARM($18.4M). CARM YTD gains are higher at: 5.229 vs. PRME (-1.027). CARM has higher annual earnings (EBITDA): -63.37M vs. PRME (-207.13M). PRME has more cash in the bank: 176M vs. CARM (26.9M). CARM has less debt than PRME: CARM (3.32M) vs PRME (41.2M). CARM has higher revenues than PRME: CARM (20.3M) vs PRME (800K).
CARMPRMECARM / PRME
Capitalization18.4M379M5%
EBITDA-63.37M-207.13M31%
Gain YTD5.229-1.027-509%
P/E RatioN/AN/A-
Revenue20.3M800K2,538%
Total Cash26.9M176M15%
Total Debt3.32M41.2M8%
FUNDAMENTALS RATINGS
CARM vs PRME: Fundamental Ratings
CARM
PRME
OUTLOOK RATING
1..100
2114
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9490
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a64

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (72) in the null industry is in the same range as CARM (94). This means that PRME’s stock grew similarly to CARM’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as CARM (100). This means that PRME’s stock grew similarly to CARM’s over the last 12 months.

PRME's SMR Rating (100) in the null industry is in the same range as CARM (100). This means that PRME’s stock grew similarly to CARM’s over the last 12 months.

PRME's Price Growth Rating (90) in the null industry is in the same range as CARM (94). This means that PRME’s stock grew similarly to CARM’s over the last 12 months.

PRME's P/E Growth Rating (100) in the null industry is in the same range as CARM (100). This means that PRME’s stock grew similarly to CARM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CARMPRME
RSI
ODDS (%)
Bullish Trend 11 days ago
90%
Bullish Trend 11 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 11 days ago
81%
Bearish Trend 11 days ago
86%
Momentum
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 11 days ago
79%
MACD
ODDS (%)
Bullish Trend 11 days ago
76%
Bullish Trend 11 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
82%
Bullish Trend 11 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
87%
Bullish Trend 11 days ago
73%
Advances
ODDS (%)
Bullish Trend 13 days ago
84%
Bullish Trend 16 days ago
76%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 20 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 11 days ago
90%
Aroon
ODDS (%)
Bearish Trend 11 days ago
81%
Bearish Trend 11 days ago
84%
View a ticker or compare two or three
Ad is loading...
CARM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CRNX37.350.87
+2.38%
Crinetics Pharmaceuticals
BRKL12.000.08
+0.67%
Brookline Bancorp
FTS41.950.20
+0.48%
Fortis
BOSC3.790.01
+0.13%
B.O.S. Better Online Solutions
TLYS4.15N/A
N/A
Tilly's

CARM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CARM has been loosely correlated with PRME. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CARM jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARM
1D Price
Change %
CARM100%
-3.46%
PRME - CARM
36%
Loosely correlated
+0.70%
SLRN - CARM
34%
Loosely correlated
N/A
CLRB - CARM
33%
Loosely correlated
+0.54%
TRDA - CARM
33%
Loosely correlated
+1.20%
EDIT - CARM
33%
Poorly correlated
-1.61%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+0.70%
CRSP - PRME
62%
Loosely correlated
+0.57%
BEAM - PRME
60%
Loosely correlated
+0.17%
NTLA - PRME
59%
Loosely correlated
+0.85%
RXRX - PRME
55%
Loosely correlated
+2.03%
ABCL - PRME
54%
Loosely correlated
+1.02%
More